CVD À¯º´·üÀÇ »ó½Â°ú °í°¨µµ POCT´Â ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ Áø´ÜÀÇ º¯ÇõÀû ¼ºÀåÀ» °ßÀÎ
¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ Áø´Ü ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ(CVD) À¯º´·ü Áõ°¡, ¸ÖƼÇ÷º½º ¹ÙÀÌ¿À¸¶Ä¿, Áø´Ü °Ë»ç ±â¼úÀÇ Áøº¸, POCT µµÀÔ·ü Çâ»ó, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÁýÁßÀûÀÎ ³ë·ÂÀ¸·Î °·ÂÇÑ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. CVD´Â ¼¼°èÀÇ »ç¸Á ¿øÀÎÀÇ »óÀ§¸¦ Â÷ÁöÇϰí ÀÖ¾î Á¶±â ¹ß°ß ¹× Á¶±â °³ÀÔÀÇ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â 2030³â¿¡´Â 2,330¸¸ ¸íÀÌ CVD·Î »ç¸ÁÇÒ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ±× Áß¿¡¼µµ ±Þ¼º ½É±Ù°æ»ö(AMI), ±Þ¼º°üÁõÈıº, ½ÉºÎÀüÀº ¿¬±¸ÀÚ¿Í ÀÇ·á Àü¹®°¡ÀÇ °¡Àå Å« °ü½ÉÀ» ¸ðÀ¸°í ÀÖ½À´Ï´Ù. ±Þ¼º ½É±Ù°æ»öÀº ¼¼°èÀûÀ¸·Î »ç¸Á ¿øÀÎÀÇ 3ºÐÀÇ 1À» Â÷ÁöÇÏ´Â ºóµµ°¡ ³ôÀº º´ÅÂÀ̱⠶§¹®¿¡ AMI´Â WHO¿¡ Áß¿äÇÑ ÃÊÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù.
RocheÀÇ Elecsys(R) Troponin Ths¿Í °°Àº AMI¿¡ ´ëÇÑ °í°¨µµ ½É±Ù Æ®·ÎÆ÷´Ñ ºÐ¼®ÀÇ Áøº¸´Â À¯·´°ú ¾Æ½Ã¾ÆÀÇ ÀÀ±Þ ºÎ¹®¿¡¼ ÇʼöÀûÀÌ µÇ¾î Áø´Ü °¡¼ÓÈ¿Í È¯ÀÚ °á°ú Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¹Ì°³Ã´ÀÇ ³ôÀº ¼ºÀå ÀáÀç·ÂÀ» °¡Áø ±Þ¼ºÀå Áö¿ªÀÔ´Ï´Ù.
½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ Áø´Ü ½ÃÀå¿¡¼ ½ÇÇè½Ç °Ë»ç¿Í POCT´Â °¢°¢ ´Ù¸¥ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÕ´Ï´Ù. ½ÇÇè½Ç °Ë»ç´Â ¹Î°¨Çϰí Á¤È®Çϸç, »ó¼¼ÇÑ À§Çè Æò°¡¿Í Áö¼ÓÀûÀÎ °üÂû¿¡ ÇʼöÀûÀÔ´Ï´Ù. ´ëÁ¶ÀûÀ¸·Î POCT´Â ȯÀÚ ¿·¿¡¼ ½Å¼ÓÇÑ °á°ú¸¦ Á¦°øÇÏ¿© ÀÀ±Þ »óȲÀ̳ª ¿ø°ÝÁö¿¡¼ ½Å¼ÓÇÑ ÀÇ»ç °áÁ¤À» ÃËÁøÇÕ´Ï´Ù. ÀÌ ¼Óµµ¿Í Á¤¹ÐµµÀÇ ±ÕÇüÀº µÎ °Ë»ç ¹æ¹ýÀÇ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ º¸ÀåÇÕ´Ï´Ù.
ÀÌ ½ÃÀåÀº ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®°ú ±â¼úÀÇ Áøº¸¿¡ ´õÇÏ¿© ºÐ¼®ÀÇ Á¤È®¼º°ú °í°¨µµÈÀÇ Áö¼ÓÀûÀÎ ÃßÁøÀ¸·Î ÀÎÇØ Áß°£ Á¤µµÀÇ °æÀï »óÅ¿¡ ÀÖ½À´Ï´Ù. ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº 6°³»ç·Î Roche Diagnostics, Abbott Rapid Diagnostics(±¸ Alere), Quidel Corporation, bioMerieux, Siemens Healthineers, Danaher CorporationÀÔ´Ï´Ù. ½ÇÇè½Ç ºÐ¼® Àåºñ´Â ±â¾÷ÀÌ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ ÀÌ ºÎ¹®Àº ÅëÇÕµÇÁö¸¸ ºÐ¼® Àåºñ´Â ¸¹Àº ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ ´õ ¼¼ºÐȵ˴ϴÙ. ½ÇÇè½ÇÀº Á¤¹Ð °Ë»ç¿Í º¹ÀâÇÑ ºÐ¼®¿¡ ÇʼöÀûÀÌ¸ç ¿©·¯ ¸¶Ä¿ ÆÐ³Î(BNP, CK-MB, ¹Ì¿À±Û·Îºó, Æ®·ÎÆ÷´Ñ µî)À» °ü¸®ÇÏ¿© ½ÉÀå °Ç° »óŸ¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ ¿¬±¸ ¼ºñ½º´Â ¼¼°è ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ Áø´Ü »ê¾÷ÀÇ °³¿ä¿Í 2024³âºÎÅÍ 2029³â±îÁö 6³â°£ ¼¼°è ½ÃÀå ¼öÀÍ ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ´ë»ó Áö¿ªÀº 4°³ Áö¿ªÀ¸·Î ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿, ºÏ¾ÆÇÁ¸®Ä«, ³²¾Æ½Ã¾Æ(MENASA), ¶óƾ¾Æ¸Þ¸®Ä«ÀÔ´Ï´Ù. ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ Áø´Ü ½ÃÀåÀÇ »ó¼¼ Á¶»ç¿¡´Â ´ÙÀ½ÀÌ Æ÷ÇԵ˴ϴÙ.
½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿´Â ½ÉÀå ¼Õ»ó°ú ½ºÆ®·¹½º¿¡ ¹ÝÀÀÇÏ¿© Ç÷¾×À¸·Î ¹æÃâµÇ´Â ¹°ÁúÀÔ´Ï´Ù. À̵éÀº ½ÉºÎÀü, ½É±Ù °æ»ö, ±Þ¼º °ü ÁõÈıº°ú °°Àº º´¸®ÇÐÀÇ Áø´Ü, À§Çè Æò°¡ ¹× °ü¸®¿¡ »ç¿ëµË´Ï´Ù. °Ë»çÀå¼Ò·Î´Â µ¶¸³°Ë»ç±â°ü, ÀÇ¿ø, ±ä±ÞÄ¡·á½Ã¼³, °³È£½Ã¼³, º´¿ø, ±¸±ÞºÎ/½Ç µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ½ÉÀå ¹ÙÀÌ¿À¸¶Ä¿ Áø´ÜÀÇ ´ë»ó ¹üÀ§¿¡´Â Àåºñ, ¼Ò¸ðǰ, ½Ã¾à, ŰƮ ¹× ºÐ¼®À» Æ÷ÇÔÇÑ °ø±Þ¾÷ü ºÐ¼®ÀÌ Æ÷ÇԵ˴ϴÙ.
Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics
The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highlighting the importance of early detection and intervention. The World Health Organization (WHO) estimates that in 2030, 23.3 million individuals will die from CVDs. Among these, acute myocardial infarction (AMI), acute coronary syndrome, and heart failure capture the greatest interest of researchers and healthcare professionals. Due to the high frequency-one-third of deaths-of this pathology globally, AMI is a key focus for WHO.
Advancements in high-sensitivity cardiac troponin assays for AMI, such as Roche's Elecsys(R) Troponin T hs make them vital in emergency departments throughout Europe and Asia, speeding up diagnosis and enhancing patient outcomes. Asia-Pacific is the fastest-growing region with high, untapped growth potential.
Lab-based and POCT segments serve critical, distinct roles in the cardiac biomarkers diagnostics market. Lab tests provide high sensitivity and precision, which is essential for detailed risk assessment and ongoing observation. In contrast, POCT delivers rapid results at the patient's side, facilitating prompt decision-making in emergencies and remote locations. This balance of speed and accuracy ensures continued demand for both testing methods.
The market is moderately competitive driven by advances in biomarkers assays and technology alongside a continuous push for enhanced accuracy and high sensitivity of assays. Six players dominate the market: Roche Diagnostics, Abbott Rapid Diagnostics (formally Alere), Quidel Corporation, bioMerieux, Siemens Healthineers, and Danaher Corporation. There are limited players in lab analyzers, making this segment consolidated, while the assays space is more fragmented owing to the presence of numerous players. Labs are essential for precise testing and complex analysis, managing multi-marker panels (e.g., BNP, CK-MB, myoglobin, and troponin) to provide a comprehensive view of cardiac health.
This research service provides an overview of the global cardiac biomarkers diagnostics industry and a 6-year global market revenue forecast from 2024 to 2029. The geographical scope covers four regions: North America, Europe, Asia-Pacific, and the Middle East, North Africa, and South Asia (MENASA) and Latin America. The detailed examination of the cardiac biomarkers diagnostics market includes:
Cardiac biomarkers are substances released into the bloodstream in response to heart damage or stress. They diagnose, assess risk, and manage conditions such as heart failure, myocardial infarction, and acute coronary syndrome. Testing locations discussed in the study include independent laboratories, physicians' offices, urgent care facilities, nursing facilities, hospitals, and emergency departments/rooms. The cardiac biomarkers diagnostics coverage includes vendor analysis encompassing instruments, consumables, reagents, kits, and assays.